title: Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
abstract: OBJECTIVE
  Aberrant expression of microRNAs (miRs) has been proved to have a role in acute myeloid leukemias (AML), but there is no information on miR-331 in AML.
  
  
  METHODS
  miR-331 expression has been analyzed using reverse-transcription polymerase chain reaction (RT-PCR) in 95 bone marrow specimens from newly diagnosed AML patients in comparison with 20 healthy subjects.
  
  
  RESULTS
  miR-331 was upregulated in AML patients and its expression seemed to influence remission achieving and death risk. The time of remission duration in patients with complete remission was longer in subjects with miR-331 downregulation after induction chemotherapy.
  
  
  CONCLUSIONS
  we showed for the first time that miR-331 higher expression appears to be correlated with worse response to therapy and shorter survival of AML patients.
authors.affiliation: 2Department of Physiology, Wroclaw Medical University, Chałubinski 10 Str, 50-368 Wroclaw, Poland.
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Butrym
authors.forename: Justyna
authors.initials: J
authors.lastname: Rybka
authors.affiliation: 3Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University, Curie-Sklodowskiej 52 Str, 50-369 Wroclaw, Poland.
authors.forename: Dagmara
authors.initials: D
authors.lastname: Baczyńska
authors.affiliation: 4Department of Epidemiology, Cancer Center-Institute of Oncology, Wybrzeże Armii Krajowej 15, 44-101 Gliwice, Poland.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Tukiendorf
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Kuliczkowski
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Mazur
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001374:Azacitidine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D055815:Young Adult
chemical_list: D035683:MicroRNAs; D003561:Cytarabine; D001374:Azacitidine; D003630:Daunorubicin
keywords: acute myeloid leukemia; expression; miR-331; prognosis; survival